Jiangsu Kanghe Biopharmaceutical

Jiangsu Kanghe Biopharmaceutical Co., Ltd. is an innovative Chinese biotechnology company focused on the research, development, and commercialization of complex pharmaceutical formulations and biological therapeutics. Founded in 2012 and headquartered in Taizhou, the company has established a diverse pipeline addressing high unmet needs in oncology, musculoskeletal diseases, and supportive care. Its clinical-stage portfolio is led by an Aprepitant injection for postoperative nausea and vomiting (Phase 3) and two novel biological assets, K1 and K11, targeting high-grade glioma and knee osteoarthritis respectively. Leveraging advanced platforms in microsphere-based drug delivery and recombinant protein engineering, the company integrates R&D capabilities in Jinan with manufacturing expertise in Shandong to deliver high-quality therapeutic solutions.